Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 4 (April)

1. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia.
   Cancer Res, 65(7): 2947-55. [Abstract] [Full-text]
2. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
   Cancer Res, 65(7): 2872-81. [Abstract] [Full-text]
3. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
   Cancer Res, 65(7): 2846-53. [Abstract] [Full-text]
4. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
   Cancer Res, 65(7): 2825-31. [Abstract] [Full-text]
5. Linkage and microarray analyses of susceptibility genes in ACI/Seg rats: a model for prostate cancers in the aged.
   Cancer Res, 65(7): 2610-6. [Abstract] [Full-text]
6. c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway.
   J Biol Chem, 280(14): 14325-30. [Abstract] [Full-text]
7. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
   Toxicol Pathol, 33(3): 386-97. [Abstract] [Full-text]
8. Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors.
   Arch Androl, 51(2): 135-9. [Abstract] [Full-text]
9. Nonparametric tests of association of multiple genes with human disease.
   Am J Hum Genet, 76(5): 780-93. [Abstract] [Full-text]
10. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
    Eur J Cancer, 41(6): 954-64. [Abstract] [Full-text]
11. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Eur J Cancer, 41(6): 941-53. [Abstract] [Full-text]
12. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.
    Eur J Cancer, 41(6): 932-40. [Abstract] [Full-text]
13. Quality of life in prostate cancer.
    Eur J Cancer, 41(6): 922-31. [Abstract] [Full-text]
14. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Eur J Cancer, 41(6): 908-21. [Abstract] [Full-text]
15. Surgical management of prostate cancer: advances based on a rational approach to the data.
    Eur J Cancer, 41(6): 888-907. [Abstract] [Full-text]
16. Molecular markers of prostate cancer outcome.
    Eur J Cancer, 41(6): 858-87. [Abstract] [Full-text]
17. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate.
    Eur J Cancer, 41(6): 846-57. [Abstract] [Full-text]
18. Changing demography of prostate cancer in Asia.
    Eur J Cancer, 41(6): 834-45. [Abstract] [Full-text]
19. Screening for prostate cancer.
    Eur J Cancer, 41(6): 825-33. [Abstract] [Full-text]
20. Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases.
    Dis Colon Rectum, 48(2): 384-9. [Abstract] [Full-text]
21. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    DNA Cell Biol, 24(4): 264-9. [Abstract] [Full-text]
22. Micturition Syncope due to paraprostatic pheochromocytoma.
    Urol Int, 74(3): 276-7. [Abstract] [Full-text]
23. Surgical outcome of radical retropubic prostatectomy is not adversely affected by preexisting three-piece inflatable penile implant.
    Urol Int, 74(3): 221-3. [Abstract] [Full-text]
24. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
    Urol Int, 74(3): 214-20. [Abstract] [Full-text]
25. Local anesthesia reduces pain associated with transrectal prostatic biopsy. A prospective randomized study.
    Urol Int, 74(3): 209-13. [Abstract] [Full-text]
26. Optimization of prostatic biopsy: a prospective randomized trial comparing the sextant biopsy with a 10-core biopsy. Impact of prostatic region of sampling.
    Urol Int, 74(3): 203-8. [Abstract] [Full-text]
27. Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer suspects.
    Urol Int, 74(3): 198-202. [Abstract] [Full-text]
28. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    J Natl Cancer Inst, 97(7): 525-32. [Abstract] [Full-text]
29. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
    Proc Natl Acad Sci U S A, 102(14): 5156-61. [Abstract] [Full-text]
30. Prostate stem cell antigen is overexpressed in prostate cancer metastases.
    Clin Cancer Res, 11(7): 2591-6. [Abstract] [Full-text]
31. Infrared spectroscopic imaging for histopathologic recognition.
    Nat Biotechnol, 23(4): 469-74. [Abstract] [Full-text]
32. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Oncogene, 24(15): 2474-82. [Abstract] [Full-text]
33. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
    Gene Ther, 12(8): 702-14. [Abstract] [Full-text]
34. Differential effects of all-trans-retinoic acid (RA) on Erk1/2 phosphorylation and cAMP accumulation in normal and malignant human prostate epithelial cells: Erk1/2 inhibition restores RA-induced decrease of cell growth in malignant prostate cells.
    Eur J Endocrinol, 152(4): 663-9. [Abstract] [Full-text]
35. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Int J Radiat Oncol Biol Phys, 61(5): 1306-16. [Abstract] [Full-text]
36. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 61(5): 1299-305. [Abstract] [Full-text]
37. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Int J Radiat Oncol Biol Phys, 61(5): 1291-8. [Abstract] [Full-text]
38. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    Int J Radiat Oncol Biol Phys, 61(5): 1285-90. [Abstract] [Full-text]
39. Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
    Cancer Sci, 96(4): 221-6. [Abstract] [Full-text]
40. 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7.
    J Biol Chem, 280(15): 14773-9. [Abstract] [Full-text]
41. Genetic variants in the vitamin D receptor gene and prostate cancer risk.
    Cancer Epidemiol Biomarkers Prev, 14(4): 997-9. [Abstract] [Full-text]
42. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
    Cancer Epidemiol Biomarkers Prev, 14(4): 993-6. [Abstract] [Full-text]
43. Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial.
    Cancer Epidemiol Biomarkers Prev, 14(4): 988-92. [Abstract] [Full-text]
44. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
    Cancer Epidemiol Biomarkers Prev, 14(4): 949-57. [Abstract] [Full-text]
45. Dietary folate and risk of prostate cancer in Italy.
    Cancer Epidemiol Biomarkers Prev, 14(4): 944-8. [Abstract] [Full-text]
46. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
    Med Hypotheses, 64(6): 1170-2. [Abstract] [Full-text]
47. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer.
    Mol Cancer Ther, 4(4): 505-15. [Abstract] [Full-text]
48. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Eur Urol, 47(5): 695-702. [Abstract] [Full-text]
49. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
    Eur Urol, 47(5): 587-92. [Abstract] [Full-text]
50. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
    Eur Urol, 47(5): 582-6. [Abstract] [Full-text]
51. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Eur Urol, 47(5): 575-80; discussion 580-1. [Abstract] [Full-text]
52. Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol.
    Eur Urol, 47(5): 569-74. [Abstract] [Full-text]
53. Two Black men with prostate cancer: a narrative approach.
    Br J Health Psychol, 10: 71-84. [Abstract] [Full-text]
54. Cryosurgical ablation of the prostate: high risk patient outcomes.
    Cancer, 103(8): 1625-30. [Abstract] [Full-text]
55. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
    Cancer, 103(8): 1615-24. [Abstract] [Full-text]
56. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Int J Cancer, 115(3): 484-92. [Abstract] [Full-text]
57. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.
    Nature, 434(7035): 921-6. [Abstract] [Full-text]
58. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer.
    Cancer Detect Prev, 29(2): 170-4. [Abstract] [Full-text]
59. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion.
    Cancer Detect Prev, 29(2): 161-9. [Abstract] [Full-text]
60. Adenosquamous carcinoma of the prostate.
    Int J Urol, 12(3): 319-21. [Abstract] [Full-text]
61. Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nerve-sparing radical retropubic prostatectomy.
    Int J Urol, 12(3): 275-9. [Abstract] [Full-text]
62. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Int J Urol, 12(3): 270-4. [Abstract] [Full-text]
63. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    J Med Chem, 48(8): 2972-84. [Abstract] [Full-text]
64. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.
    Cancer Res, 65(8): 3447-53. [Abstract] [Full-text]
65. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
    Cancer Res, 65(8): 3404-9. [Abstract] [Full-text]
66. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Cancer Res, 65(8): 3328-35. [Abstract] [Full-text]
67. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
    Cancer Res, 65(8): 3108-16. [Abstract] [Full-text]
68. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.
    Cancer Res, 65(8): 3081-91. [Abstract] [Full-text]
69. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.
    Cancer Res, 65(8): 3030-4. [Abstract] [Full-text]
70. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer.
    Cancer Res, 65(8): 2990-2. [Abstract] [Full-text]
71. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    J Clin Oncol, 23(12): 2789-96. [Abstract] [Full-text]
72. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
    J Clin Oncol, 23(12): 2772-80. [Abstract] [Full-text]
73. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Clin Cancer Res, 11(8): 3065-74. [Abstract] [Full-text]
74. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
    Clin Cancer Res, 11(8): 2883-8. [Abstract] [Full-text]
75. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
    Vaccine, 23(24): 3114-22. [Abstract] [Full-text]
76. The continuing role of fine-needle aspiration of the prostate gland into the 21st century: a tribute to Torsten Löwhagen.
    Diagn Cytopathol, 32(5): 315-20. [Abstract] [Full-text]
77. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
    J Exp Med, 201(8): 1257-68. [Abstract] [Full-text]
78. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
    Cancer Immunol Immunother, 54(6): 571-6. [Abstract] [Full-text]
79. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis.
    Thromb Haemost, 93(4): 770-8. [Abstract] [Full-text]
80. Is prostate-specific membrane antigen a multifunctional protein?
    Am J Physiol Cell Physiol, 288(5): C975-81. [Abstract] [Full-text]
81. Angiotropism of human prostate cancer cells: implications for extravascular migratory metastasis.
    BJU Int, 95(7): 1099-103. [Abstract] [Full-text]
82. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?
    BJU Int, 95(7): 969-71. [Abstract] [Full-text]
83. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
    BJU Int, 95(7): 963-8. [Abstract] [Full-text]
84. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    BJU Int, 95(7): 961-2. [Abstract] [Full-text]
85. Early outcomes of active surveillance for localized prostate cancer.
    BJU Int, 95(7): 956-60. [Abstract] [Full-text]
86. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
    BJU Int, 95(7): 951-5. [Abstract] [Full-text]
87. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.
    J Clin Invest, 115(4): 959-68. [Abstract] [Full-text]
88. Detection and correction of patient movement in prostate brachytherapy seed reconstruction.
    Phys Med Biol, 50(9): 2071-87. [Abstract] [Full-text]
89. Portrayals of treatment decision-making on popular breast and prostate cancer web sites.
    Eur J Cancer Care (Engl), 14(2): 171-4. [Abstract] [Full-text]
90. Endocrine approaches in the therapy of prostate carcinoma.
    Hum Reprod Update, 11(3): 309-17. [Abstract] [Full-text]
91. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.
    Br J Cancer, 92(8): 1538-44. [Abstract] [Full-text]
92. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer.
    J Clin Epidemiol, 58(5): 466-74. [Abstract] [Full-text]
93. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
    Transplant Proc, 37(2): 958-9. [Abstract] [Full-text]
94. Marriage and ethnicity predict treatment in localized prostate carcinoma.
    Cancer, 103(9): 1819-25. [Abstract] [Full-text]
95. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
    Cancer, 103(9): 1833-42. [Abstract] [Full-text]
96. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy.
    Cancer, 103(9): 1826-32. [Abstract] [Full-text]
97. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Int J Cancer, 115(4): 630-40. [Abstract] [Full-text]
98. Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer.
    Eval Health Prof, 28(2): 142-59. [Abstract] [Full-text]
99. Modulation of radiation response by histone deacetylase inhibition.
    Int J Radiat Oncol Biol Phys, 62(1): 223-9. [Abstract] [Full-text]
100. High-dose regions versus likelihood of cure after prostate brachytherapy.
     Int J Radiat Oncol Biol Phys, 62(1): 170-4. [Abstract] [Full-text]
101. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
     Int J Radiat Oncol Biol Phys, 62(1): 164-9. [Abstract] [Full-text]
102. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer.
     Int J Radiat Oncol Biol Phys, 62(1): 154-63. [Abstract] [Full-text]
103. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
     Int J Radiat Oncol Biol Phys, 62(1): 148-53. [Abstract] [Full-text]
104. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.
     Int J Radiat Oncol Biol Phys, 62(1): 3-19. [Abstract] [Full-text]
105. Men's experiences of physical exams and cancer screening tests: a qualitative study.
     Prev Med, 40(6): 628-35. [Abstract] [Full-text]
106. 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids.
     Prostaglandins Leukot Essent Fatty Acids, 72(5): 363-72. [Abstract] [Full-text]
107. Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells.
     Arch Biochem Biophys, 437(2): 151-8. [Abstract] [Full-text]
108. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T.
     Magn Reson Med, 53(5): 1033-9. [Abstract] [Full-text]
109. In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-resolved PRESS at 3 T.
     Magn Reson Med, 53(5): 1177-82. [Abstract] [Full-text]
110. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination.
     Vaccine, 23(27): 3565-71. [Abstract] [Full-text]
111. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
     Proc Natl Acad Sci U S A, 102(17): 6201-6. [Abstract] [Full-text]
112. Fluorocholine PET/CT in patients with prostate cancer: initial experience.
     Radiology, 235(2): 623-8. [Abstract] [Full-text]
113. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
     J Pain Symptom Manage, 29(4): 352-7. [Abstract] [Full-text]
114. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
     J Clin Oncol, 23(13): 2918-25. [Abstract] [Full-text]
115. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
     J Clin Oncol, 23(13): 2911-7. [Abstract] [Full-text]
116. Genetic changes in localized prostate cancer of Japanese patients shown by comparative genomic hybridization.
     Cancer Genet Cytogenet, 159(1): 84-8. [Abstract] [Full-text]
117. Molecular characterization of a consistent 4.5-megabase deletion at 4q28 in prostate cancer cells.
     Cancer Genet Cytogenet, 159(1): 18-26. [Abstract] [Full-text]
118. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
     J Steroid Biochem Mol Biol, 93(2): 191-200. [Abstract] [Full-text]
119. Calcidiol and prostate cancer.
     J Steroid Biochem Mol Biol, 93(2): 183-90. [Abstract] [Full-text]
120. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells.
     J Steroid Biochem Mol Biol, 93(2): 167-72. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.